Ropes & Gray has advised Mirador Therapeutics in its exclusive worldwide license agreement with Kira Pharmaceuticals. Mirador Therapeutics, Inc., a clinical-stage precision medicine company, has entered...
Mirador Therapeutics Secures Exclusive Worldwide License for Anti-C5a Antibody KP-301 from Kira Pharmaceuticals
Lepu Biopharma’s $1.6 Billion ADC Licensing Agreement with ArriVent Biopharma
Ropes & Gray represented Lepu Biopharma in the transaction. Shanghai-based Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) announced an exclusive license agreement with ArriVent BioPharma (Nasdaq:...
Sanofi’s Investment in Resalis Therapeutics
Ropes & Gray advised Sanofi on the deal. Sanofi announced a strategic equity investment in Torino, Italy-based Resalis Therapeutics (Resalis Therapeutics). The company plans to use...
ImmunoGen’s Multi-Target License and Option Agreement with ImmunoBiochem
Ropes & Gray represented ImmunoGen in the deal. ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation on the...
Ginkgo Bioworks and Bayer’s Collaboration to Build Agricultural Biologicals R&D Platform
Ropes & Gray advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, a horizontal platform for cell programming, announced the closing a transaction with Bayer for a...
Ginkgo Bioworks’ $83 Million Collaboration With Bayer
Ropes & Gray advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, a horizontal platform for cell programming, signed an agreement with Bayer to expand Ginkgo’s platform capabilities...
Verastem Oncology’s Collaboration With Mirati Therapeutics
Ropes & Gray advised Verastem Oncology in the deal. Verastem Oncology announced a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug...